vs
CAPRICOR THERAPEUTICS, INC.（CAPR）与Maase Inc.（MAAS）财务数据对比。点击上方公司名可切换其他公司
CAPRICOR THERAPEUTICS, INC.的季度营收约是Maase Inc.的1.1倍（$11.1M vs $9.9M），CAPRICOR THERAPEUTICS, INC.自由现金流更多（$-15.3M vs $-18.3M）
Capricor Therapeutics是一家处于临床阶段的生物技术企业，专注于研发及商业化细胞疗法、基因疗法等创新生物制剂，覆盖罕见病、心血管疾病、肌肉疾病等领域，主要面向美国市场，致力为治疗选择有限的患者填补未被满足的医疗需求。
CAPR vs MAAS — 直观对比
营收规模更大
CAPR
是对方的1.1倍
$9.9M
自由现金流更多
CAPR
多$3.0M
$-18.3M
损益表 — Q4 FY2024 vs Q2 FY2023
| 指标 | | |
|---|---|---|
| 营收 | $11.1M | $9.9M |
| 净利润 | $-7.1M | — |
| 毛利率 | — | 78.7% |
| 营业利润率 | -69.1% | -55.9% |
| 净利率 | -63.9% | — |
| 营收同比 | -7.9% | — |
| 净利润同比 | -833.8% | — |
| 每股收益（稀释后） | $-0.11 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CAPRMAAS
| Q4 24 | $11.1M | — | ||
| Q3 24 | $2.3M | — | ||
| Q2 24 | $4.0M | — | ||
| Q1 24 | $4.9M | — | ||
| Q4 23 | $12.1M | — | ||
| Q3 23 | $6.2M | — | ||
| Q2 23 | $3.9M | — | ||
| Q1 23 | $3.0M | — |
净利润CAPRMAAS
| Q4 24 | $-7.1M | — | ||
| Q3 24 | $-12.6M | — | ||
| Q2 24 | $-11.0M | — | ||
| Q1 24 | $-9.8M | — | ||
| Q4 23 | $-762.1K | — | ||
| Q3 23 | $-6.4M | — | ||
| Q2 23 | $-7.4M | — | ||
| Q1 23 | $-7.8M | — |
营业利润率CAPRMAAS
| Q4 24 | -69.1% | — | ||
| Q3 24 | -575.2% | — | ||
| Q2 24 | -291.9% | — | ||
| Q1 24 | -209.2% | — | ||
| Q4 23 | -10.6% | — | ||
| Q3 23 | -111.0% | — | ||
| Q2 23 | -197.8% | — | ||
| Q1 23 | -274.0% | — |
净利率CAPRMAAS
| Q4 24 | -63.9% | — | ||
| Q3 24 | -555.2% | — | ||
| Q2 24 | -277.0% | — | ||
| Q1 24 | -199.6% | — | ||
| Q4 23 | -6.3% | — | ||
| Q3 23 | -103.3% | — | ||
| Q2 23 | -188.0% | — | ||
| Q1 23 | -260.1% | — |
每股收益（稀释后）CAPRMAAS
| Q4 24 | $-0.11 | — | ||
| Q3 24 | $-0.38 | — | ||
| Q2 24 | $-0.35 | — | ||
| Q1 24 | $-0.31 | — | ||
| Q4 23 | $0.02 | — | ||
| Q3 23 | $-0.25 | — | ||
| Q2 23 | $-0.29 | — | ||
| Q1 23 | $-0.31 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $151.5M | $10.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $145.5M | $31.6M |
| 总资产 | $170.5M | $47.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CAPRMAAS
| Q4 24 | $151.5M | — | ||
| Q3 24 | $85.0M | — | ||
| Q2 24 | $29.5M | — | ||
| Q1 24 | $39.9M | — | ||
| Q4 23 | $39.5M | — | ||
| Q3 23 | $28.5M | — | ||
| Q2 23 | $37.8M | — | ||
| Q1 23 | $45.2M | — |
股东权益CAPRMAAS
| Q4 24 | $145.5M | — | ||
| Q3 24 | $68.3M | — | ||
| Q2 24 | $11.5M | — | ||
| Q1 24 | $18.4M | — | ||
| Q4 23 | $22.6M | — | ||
| Q3 23 | $-1.8M | — | ||
| Q2 23 | $2.7M | — | ||
| Q1 23 | $6.2M | — |
总资产CAPRMAAS
| Q4 24 | $170.5M | — | ||
| Q3 24 | $93.0M | — | ||
| Q2 24 | $38.3M | — | ||
| Q1 24 | $49.4M | — | ||
| Q4 23 | $58.7M | — | ||
| Q3 23 | $37.2M | — | ||
| Q2 23 | $46.0M | — | ||
| Q1 23 | $53.9M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.8M | $-18.2M |
| 自由现金流经营现金流 - 资本支出 | $-15.3M | $-18.3M |
| 自由现金流率自由现金流/营收 | -137.3% | -184.4% |
| 资本支出强度资本支出/营收 | 4.4% | 1.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-41.2M | — |
8季度趋势，按日历期对齐
经营现金流CAPRMAAS
| Q4 24 | $-14.8M | — | ||
| Q3 24 | $-11.6M | — | ||
| Q2 24 | $-12.3M | — | ||
| Q1 24 | $-1.3M | — | ||
| Q4 23 | $-11.6M | — | ||
| Q3 23 | $-8.8M | — | ||
| Q2 23 | $-9.4M | — | ||
| Q1 23 | $4.2M | — |
自由现金流CAPRMAAS
| Q4 24 | $-15.3M | — | ||
| Q3 24 | $-11.7M | — | ||
| Q2 24 | $-12.3M | — | ||
| Q1 24 | $-1.9M | — | ||
| Q4 23 | $-12.2M | — | ||
| Q3 23 | $-9.1M | — | ||
| Q2 23 | $-9.6M | — | ||
| Q1 23 | $3.9M | — |
自由现金流率CAPRMAAS
| Q4 24 | -137.3% | — | ||
| Q3 24 | -515.2% | — | ||
| Q2 24 | -310.9% | — | ||
| Q1 24 | -38.3% | — | ||
| Q4 23 | -100.5% | — | ||
| Q3 23 | -146.5% | — | ||
| Q2 23 | -243.9% | — | ||
| Q1 23 | 129.3% | — |
资本支出强度CAPRMAAS
| Q4 24 | 4.4% | — | ||
| Q3 24 | 0.4% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 12.4% | — | ||
| Q4 23 | 4.6% | — | ||
| Q3 23 | 4.4% | — | ||
| Q2 23 | 3.5% | — | ||
| Q1 23 | 11.6% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CAPR
暂无分部数据
MAAS
| Wealth management | $7.8M | 78% |
| Insurance consulting | $1.0M | 10% |
| Other | $975.0K | 10% |
| Asset management | $168.0K | 2% |
